New Data From REZOLVE-AD Study Of Rezpegaldesleukin Presented In Late-Breaking Oral Abstract Presentation At ACAAI 2025 Annual Scientific Meeting. Statistically significant and clinically meaningful i ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

Learn more about whether BioMarin Pharmaceutical Inc. or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ ...

Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s ability to improve urticaria control from the Company’s recently completed Phase 2 ...

Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment ...

Nektar Therapeutics NKTR reported a loss of $1.87 per share for the third quarter of 2025, narrower than the Zacks Consensus ...

Dupixent is prescribed to asthma patients as well as for treatment of chronic obstructive pulmonary disease (COPD), chronic sinusitis, nasal polyps, eosinophilic esophagitis, and moderate to severe ...

First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

Zoetis, Inc. ZTS delivered third-quarter 2025 adjusted earnings (excluding one-time items) of $1.70 per share, which surpassed the Zacks Consensus Estimate of $1.62. In the year-ago quarter, the ...

Abrocinitib was slightly more effective than dupilumab in treating atopic dermatitis, both in White patients and in patients with skin of color.